Transcatheter aortic valve implantation (TAVI) has become an established treatment option for severe aortic stenosis in patients at high risk of surgical aortic valve replacement [1, 2] . Recent studies, such as PARTNER-2 [3] and NOTION [4] have expanded the possible use of TAVI to patients at intermediate surgical risk. With increasing life expectancy of patients undergoing TAVI, the issue of valve durability becomes increasingly important. As yet, there is a paucity of data on the antithrombotic regimen following TAVI, although reports on many thousands TAVI procedures have been published [5] , demonstrating excellent outcomes in all risk categories [6] . Until recently, much investigated safety issues in TAVI were risk of access vessel complications [7, 8] , stroke, or pacemaker implantation, all of which have decreased substantially [9] [10] [11] [12] , resulting in an increasing global uptake of the approach. Changes in prosthesis leaflet morphology and function shortly after TAVI only gained interest in 2014, when a review of single case reports identified 16 clinical events of transcatheter valve thrombosis during 2002-2012 [13] . Increasing trans-valvular gradients on echocardiography (from 10 to 42 mmHg) were noted in these patients presented with dyspnea as the most common symptom.
Anticoagulation with vitamin K antagonist (warfarin) effectively restored hemodynamics within 2 months.
When considering prosthetic valve deterioration, it is important not to mix structural, hemodynamic and clinical readouts, and endpoints. According to standardized endpoint definitions on TAVI by the Valve Academic Research Consortium, valve thrombosis is defined as ''Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment'' [14] . To this extent, recent studies used new generation computer tomography (CT) to visualize morphological changes (such as leaflet thickening or thrombosis) not visible in echocardiography [15] . These changes do not necessarily correlate with hemodynamic changes (i.e. rise in pressure gradient) and probably even less with clinical events, such as dyspnea, heart failure or stroke, although clinical endpoints do of course need larger studies and longer followup.
In 2015, reduced bioprosthetic leaflet motion was incidentally observed in a patient who had a stroke in a clinical trial investigating a novel transcatheter valve system (Portico valve). Subsequent analyses of available CT scans from this trial together with two registries were published in the same year [16] . Makkar et al. [16] reported reduced leaflet motion on CT in 40% (20 of 55 patients) in the clinical trial and 13% (17 of 132 patients) in the two registries. Notably, none of the patients on warfarin showed reduced leaflet motion. Leaflet motion in patients on dual platelet inhibition (aspirin and clopidogrel, DAPT) was normalized by initiation of anticoagulation. The authors also found a hint towards more strokes or transitory ischemic attacks (TIA) in patients with reduced valve leaflet motion (3 vs. 1 in patients with normal leaflet motion). Importantly, reduced leaflet motion occurred in both TAVI and surgically implanted valves and was not associated with increased transvalvular gradients as measured by echocardiography.
A recently published registry of 1521 patients after TAVI with serial echocardiographic follow-up reported the incidence of valve hemodynamic deterioration (VHD), defined as an increase of C10 mmHg in transvalvular gradient compared to discharge [17] . The authors documented VHD in 4.5% of the patients. Next to procedural issues (valve-in-valve implantation [18] , small valve size), the absence of anticoagulation was a predictor of VHD, suggesting morphological changes and possibly leaflet thrombus as the underlying mechanisms. In this study, functional (echocardiography) and not structural (CT) assessments were used. During a 4-year follow-up, no difference in (cardiovascular) death or stroke was observed.
The largest cohort of patients with transcatheter heart valve (THV) changes was published by the Milan group, who presented multicenter data on 4266 patients undergoing TAVI [19] . The authors defined THV dysfunction as a mean gradient of 20 mmHg on echocardiography, and THV thrombosis when according changes visualized in echo, CT, or histopathology. While patients were not systematically screened, 26 THV thromboses (0.6%) were noted, which was reported to be clinically significant (dyspnea) in two-thirds (n = 17). In these patients, the mean pressure gradient was described to formally fulfill the criteria of a relevant aortic stenosis (41 mmHg). Anticoagulation normalized pressure gradients in the majority of the patients (88%) within two months.
Routine multi-detector CT (MDCT) was performed in 460 consecutive patients in a Danish study 1 and 3 months following TAVI [20] . Hypo-attenuated leaflet thickening was regarded indicative of valve thrombosis. THV thrombosis was reported in 7% of the patients, of whom the majority was asymptomatic, but 18% showed clinical symptoms. Again, THV thrombosis was more common (relative risk 6.1, confidence interval: 1.9-19.8, p \ 0.001) in patients not on anticoagulant but antiplatelet therapy. Using MDCT and transesophageal echo showed reversal of valve thrombosis and function in 85% of patients by warfarin treatment.
In the current issue of the journal, Ruile et al. present follow-up data on TAVI prosthesis deterioration in relation to patient's antithrombotic regime [21] . A total of 51 patients with leaflet thickening as detected by MDCT were examined. Until May 2015, patients with leaflet thrombosis were treated with vitamin K antagonist (phenprocoumon) and clopidogrel for 3 months (22 out of 528 patients undergoing routine MDCT scans following TAVI). Following May 2015, in patients with leaflet thickening, anticoagulation was only initiated in an established indication for anticoagulation (e.g. atrial fibrillation, n = 9), the remaining 22 patients were treated with DAPT. While leaflet thickening/restriction increased in the DAPT group, it regressed significantly in the anticoagulated group. The change in CT-derived morphological valvular pathologies was significantly different between the two groups analyzed. Of note, following discontinuation of anticoagulation, leaflet pathologies relapsed, with significant recurrences of leaflet restriction and thrombus extent. Interestingly, the change in pressure gradient as measured by echocardiography correlated with the change in leaflet restriction. However, none of the patients reported clinically apparent symptoms relative to THV thrombosis. Some of the findings of the current report are confirmatory of earlier analyses by the same group and by Makkar et al. Fig. 1 The influence of prosthetic valve type (balloon vs. selfexpandable) and mode of implantation (surgical vs. transcatheter valve) (left side) possibly influences the course of leaflet alterations. These can most sensitively be detected by computer tomography, while transthoracic echo offers better functional insights and transesophageal echo allows a higher temporal resolution. Antithrombotic strategies currently under prospective evaluation are depicted on the right side [16] and Hansson et al. [20] . However, progression of leaflet thickening under DAPT and, particularly, possible recurrence after discontinuation of anticoagulation therapy are important novel findings. The authors published a smaller series (n = 156 CTs in TAVI (Sapien S3) patients) earlier this year, in which they report hypo-attenuated leaflet thickening to occur in 16 patients (10.3%) [22] . Interestingly, in that study, valve thrombosis was not linked to lack of anticoagulation therapy at baseline, while it was reversible by initiation of anticoagulation therapy.
As acknowledged also by the authors, the non-randomized and non-prospective, single-center nature of the current study represent limitations. Therapeutic decisions were left at the discretion of the treating physician; therefore, treatment bias cannot be fully excluded. The case series including follow-up does, however, provide an excellent basis for further prospective, randomized trials comparing anticoagulation (vitamin K antagonist or NOAC [23] ) with antiplatelet therapy in patients with TAVI. Several of these studies are currently enrolling patients, mostly with hard clinical endpoints (death, myocardial infarction, stroke, bleeding, thrombosis) ( Table 1) .
The question remains if the issues described are specific for TAVI bioprostheses or occur in surgical aortic valve replacement as well. In the latter, structural valve degeneration has been reported to occur at a rate of 20-30% after 10 years of implantation [24] . Reports on valve thrombosis in surgically inserted bioprosthesis vary in the literature and reach up to 5%, but these data were acquired before MDCT became available and could, therefore, be higher. In a series of 397 explanted biological valves, Egbe et al. found bioprosthetic valve thrombosis at a rate of 11.6% [25] . Here, subtherapeutic INR was a strong predictor of valve thrombosis.
Notwithstanding the clinical relevance of the current findings, it is important to note that mid-to long-term clinical outcomes following TAVI have been excellent. Recent reports (presented at EuroPCR 2016 by Danny Dvir) on long-term follow-up of patients undergoing balloon-expandable first-generation valves, provide hints of valve degeneration (more regurgitation than stenosis) that were, interestingly, not linked to anticoagulant therapy but to the presence of comorbidities, such as chronic kidney disease. The authors reported a better than 90% valve patency up to 5 years followed by accelerated valve degeneration between 5 and 7 years. However, these findings have been questioned due to methodological flaws of the Kaplan-Meier analysis used including limited patient numbers at risk at the later time points [26] .
As demonstrated in the long-term follow-up analysis of the PARTNER trial, 5-year function of TAVI prosthesis (n = 3105 patients) is good (i.e. no structural valve deterioration requiring surgery), providing reassurance about the long-term durability [27] . Particularly, there was no difference in transvalvular pressure gradient between the TAVI and the surgical group (mean gradient 10.7 vs. 10.6 mmHg). In the intermediate risk PARTNER 2 trial, pressure gradients were even lower following TAVI than after conventional surgery (2-year follow-up data available) [3] .
What do the different outcome measures yielded by different diagnostic strategies tell us? To reliably detect leaflet thickening and valve thrombosis, CT would have to be performed on a routine basis in all patients. Transesophageal echocardiography is, however, superior in terms of temporal resolution. Because of the discrepancy between clinical outcomes and rate of leaflet thickening, functional analysis, i.e. (transthoracic) echocardiography, might be sufficient to identify those patients with hemodynamically relevant valve obstruction by thrombotic material. If currently ongoing studies provide evidence that anticoagulant therapy is indeed necessary, valve morphological and functional deterioration might (again) become rare. In the meantime, prescribing anticoagulant instead of antiplatelet therapy not only in patients with concomitant atrial fibrillation but in all patients following TAVI at low or intermediate bleeding risk might become an option (Fig. 1) . Weighing the benefits for anticoagulation using the CHA 2 DS 2 -Vasc score may also be an option in TAVI patients without atrial fibrillation [28] . In patients with concomitant atrial fibrillation, combination of antiplatelet with anticoagulation therapy seems not to reduce ischemic events, but increases bleeding complications, as suggested by a recent retrospective analysis in 621 patients [29] , indicating that the combination of anticoagulant with antiplatelet therapy may worsen outcome. Of note, relying on CT for a diagnosis of valve deterioration might be misleading in the end, owing to its morphological rather than functional character. The few clinical events demonstrated in currently available reports are in contrast to the apparent frequency of valve alterations. Regression of the parameters described following initiation of anticoagulation will also have to be scrutinized in a prospective fashion.
Findings on bioprosthetic valve deterioration are increasingly important when intermediate or low risk patients undergo TAVI and also surgical bioprosthesis implantation. Both, the ESC 2012 [30] and AHA 2014 [31] guidelines assign anticoagulation therapy only a class IIb indication following surgical aortic bioprosthesis implantation. Given the data on both transcatheter but also surgical valve deterioration, opting for a more aggressive strategy here might be necessary. 
